Tianqing Chu

机构：Shanghai Chest Hospital · ORCID：0000-0002-0744-0397

发表论文 111 篇 · 总被引 1693 次 · h-index 22

代表论文

• Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer (2024 · Journal for ImmunoTherapy of Cancer · 被引 19)
• Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study (2024 · BMC Medicine · 被引 14)
• Coinhibition of the MEK/RTK pathway has high therapeutic efficacy in KRAS-mutant non-small cell lung cancer (2025 · Signal Transduction and Targeted Therapy · 被引 12)
• Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial (2025 · 癌症：英文版 · 被引 11)
• YY1 downregulation underlies therapeutic response to molecular targeted agents (2024 · Cell Death and Disease · 被引 11)
• Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors (2024 · European Journal of Cancer · 被引 9)